Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
First in, best health: treat HIV now

It may be over 30 years since HIV hit the world, but it’s only recently that a study finally revealed the sooner a person diagnosed with HIV begins taking antiretroviral medication, the better it is for their long-term health outcomes. In light of this, the Victorian AIDS Council (VAC) and Living Positive Victoria (LPV) have teamed up to launch their first ever social marketing campaign dedicated solely to early treatment: Treat HIV Now.

Published
26 April 2016
From
Star Observer
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover all remaining lower middle-income countries. The amendment to the 2014 licence specifically allows generic medicine distribution in four countries with patents - Armenia, Moldova, Morocco and Ukraine - that were not covered in the initial agreement. MPP sub-licensees can now sell in countries that are home to 94% of people living with HIV in the developing world.

Published
25 April 2016
From
ViiV Healthcare press release
Multiple social and health factors associated with irregular attendance at London HIV clinics

People who miss appointments for HIV care are more likely to have money problems, childcare responsibilities and a history of depression according to a recent UK study. While

Published
22 April 2016
By
Roger Pebody
AIDS Treatment in Haiti Promising for Developing Nations

One of the first groups of HIV patients in a poor country to get free AIDS drugs has about the same survival rate as their closest counterparts in the United States, according to scientists at Weill Cornell Medical College.

Published
19 April 2016
From
The New York Times
Outbreak of high level azithromycin resistant gonorrhoea in England

There have been 34 cases of high level azithromycin resistant gonorrhoea amongst residents of England between November 2014 and April 2016. The outbreak spread from the north of England to the West Midlands and south of England, including London. Initial cases were among heterosexuals but more recent evidence suggests high level azithromycin resistant gonorrhoea is now spreading among men who have sex with men.

Published
15 April 2016
From
Public Health England
People who use drugs still adherent to PrEP

New research conducted with a group of PrEP clients at the San Francisco AIDS Foundation PrEP clinic suggests that people who use substances adhere to PrEP and stay in care at about the same rate as people who do not use drugs.

Published
13 April 2016
From
BETA blog
People not taking HIV treatment feel under pressure to ‘do the right thing’

Australian people living with HIV who have chosen not to take antiretrovirals and who have doubts about HIV medicine report feeling excluded and silenced within HIV organisations

Published
13 April 2016
By
Roger Pebody
Resistance to anti-HIV drugs in steep decline in Switzerland

Prevalence of antiretroviral drug resistance has declined significantly among patients in Switzerland, investigators report in the online edition of Clinical Infectious Diseases. As many as 57% of

Published
13 April 2016
By
Michael Carter
HIV took just 2 weeks to overcome our best attempt to edit it out of our cells

We all got really excited a few weeks ago when researchers announced they'd removed HIV from human immune cells using new gene-editing technology called CRISPR/Cas-9, or 'CRISPR' for short, which works like a pair of molecular scissors to cut and paste DNA. As far as we know, that specific result is holding up just fine, but a separate study has now revealed that, worryingly, HIV can evolve to survive CRISPR attacks in just two weeks. Even worse, the attack itself could actually be introducing mutations that make the virus stronger.

Published
11 April 2016
From
ScienceAlert

Filter by country